SLC5A2 and diabetic ketoacidosis: Although there are currently no defined therapeutic guidelines for this disease, sodium and glucose cotransporter 2 (SGLT2) inhibitors should not be used in LADA patients due to the increased risk of diabetic ketoacidosis [20–22].